The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | MARIPOSA: follow-up of lazertinib with amivantamab or osimertinib in EGFR-m NSCLC
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, provides updates from the Phase III MARIPOSA study (NCT04487080), which assessed first-line lazertinib with amivantamab or osimertinib in patients with EGFR-mutant non-small cell lung cancer. Patients receiving lazertinib with amivantamab continue to have improved long-term survival and is well tolerated. Infusion-related reactions is additionally addressed in the PALOMA-3 trial (NCT05388669), where subcutaneous amivantamab is given to patients. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
